Association for Clinical Oncology
Professional organization for physicians and oncology professionals.
Based in VA
AI Overview
With $1.4M in lobbying spend across 23 quarterly filings, Association for Clinical Oncology is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2020 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $280K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Budget/Appropriations
Issues related to oncology care, physician reimbursement, research funding, and the cost of prescription drugs. Issues related to HR 913, the CLINICAL Treatment Act
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs. Issues related to HR 913/S 4742, the CLINICAL Treatment Act
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs.
H.R. 1868, Medicare Sequester.
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act.
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act; Issues related to FDA user fee agreements, Consolidated Appropriations Act, 2022 (PL 117-103).
Issues related to research funding, Consolidated Appropriations Act, 2022 (PL 117-103).
Showing 8 of 17 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.